অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 345.39 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: povidone; calcium hydrogen phosphate dihydrate; silicon dioxide; lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; titanium dioxide; hypromellose; macrogol 4000 - quetiapine sandoz is indicated for:,bipolar disorder adults ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dose and method of administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years ? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years) ? treatment of schizophrenia

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 28.78 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; silicon dioxide; iron oxide yellow; sodium starch glycollate type a; povidone; magnesium stearate; iron oxide red; calcium hydrogen phosphate dihydrate; titanium dioxide; hypromellose; macrogol 4000 - quetiapine sandoz is indicated for:,bipolar disorder adults ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dose and method of administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years ? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years) ? treatment of schizophrenia

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - quetiapine fumarate, quantity: 230.26 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; lactose monohydrate; magnesium stearate; silicon dioxide; povidone; calcium hydrogen phosphate dihydrate; titanium dioxide; hypromellose; macrogol 4000 - quetiapine sandoz is indicated for:,bipolar disorder adults ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder (see dose and method of administration) ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years ? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years) ? treatment of schizophrenia

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gabapentin, quantity: 300 mg - capsule - excipient ingredients: maize starch; colloidal anhydrous silica; purified talc; pregelatinised maize starch; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate - gabapentin sandoz is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard antiepileptic medicines..,gabapentin sandoz is indicated for the treatment of neuropathic pain.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - gabapentin, quantity: 400 mg - capsule - excipient ingredients: maize starch; pregelatinised maize starch; purified talc; colloidal anhydrous silica; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate - gabapentin sandoz is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard antiepileptic medicines..,gabapentin sandoz is indicated for the treatment of neuropathic pain.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 20 mg - tablet, modified release - excipient ingredients: hypromellose; copovidone; microcrystalline cellulose; medium chain triglycerides; titanium dioxide; magnesium stearate; maize starch; stearic acid; lactose monohydrate; colloidal anhydrous silica; behenoyl polyoxyglycerides; hydrogenated castor oil; iron oxide red - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 40 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; hypromellose; titanium dioxide; lactose monohydrate; colloidal anhydrous silica; hydrogenated castor oil; iron oxide yellow; medium chain triglycerides; magnesium stearate; stearic acid; behenoyl polyoxyglycerides; copovidone; maize starch - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 5 mg - tablet, modified release - excipient ingredients: maize starch; lactose monohydrate; stearic acid; hypromellose; colloidal anhydrous silica; medium chain triglycerides; indigo carmine aluminium lake; titanium dioxide; behenoyl polyoxyglycerides; copovidone; magnesium stearate; microcrystalline cellulose; hydrogenated castor oil - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 10 mg - tablet, modified release - excipient ingredients: titanium dioxide; stearic acid; behenoyl polyoxyglycerides; copovidone; maize starch; lactose monohydrate; magnesium stearate; hydrogenated castor oil; hypromellose; colloidal anhydrous silica; microcrystalline cellulose; medium chain triglycerides - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxycodone hydrochloride, quantity: 80 mg - tablet, modified release - excipient ingredients: copovidone; colloidal anhydrous silica; lactose monohydrate; behenoyl polyoxyglycerides; titanium dioxide; hydrogenated castor oil; stearic acid; magnesium stearate; medium chain triglycerides; maize starch; microcrystalline cellulose; hypromellose; iron oxide black; colour - oxycodone sandoz modified release tablet is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. oxycodone sandoz modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. oxycodone sandoz modified release tablet is not indicated as an as-needed (prn) analgesia.